Peer Reviewed
Rheumatology clinic

Haemophilic arthropathy: can it be prevented?

Matthew Js Parker, Liane Khoo, Jane F Bleasel
Abstract
Safe and effective replacement clotting factor concentrates are available for treating patients with haemophilia, but challenges remain in the management of haemophilic arthropathy. Primary prophylaxis with additional on-demand treatment offers the optimal management strategy for minimising long-term joint damage.
Key Points

    Patients with haemophilia are characteristically at risk of spontaneous haemorrhage, and haemophilic arthropathy is the single major cause of morbidity.1,2 Recurrent haemarthrosis, which accounts for approximately 70 to 80% of bleeding episodes, is the predominant cause of chronic disability (Figure 1).3 Spontaneous bleeds also occur in muscle, soft tissue, other organs and the central nervous system but are less common. Despite the availability of safe and effective treatment for haemophilia, most commonly in the form of replacement clotting factor concentrates, the prevention and management of joint bleeds remain challenging.

    Picture credit: © Chris Wikoff, 2016

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?